<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-38808" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mirabegron</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dawood</surname>
            <given-names>Omar</given-names>
          </name>
          <aff>Southern Illinois University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>El-Zawahry</surname>
            <given-names>Ahmed</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Omar Dawood declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ahmed El-Zawahry declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-38808.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Mirabegron is a medication used in the management of overactive bladder. It is in the sympathomimetic class of medications. It received approval from the US Food and Drug Administration (FDA) in June 2012 for treating overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. This activity reviews the indications, action, and contraindications for mirabegron as a valuable agent in the management of overactive bladder, including the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the care of patients with overactive bladder and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of mirabegron.</p></list-item><list-item><p>Review the indications for initiating therapy with mirabegron.</p></list-item><list-item><p>Outline the possible adverse effects associated with mirabegron.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance care delivery for patients who can benefit from mirabegron therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38808&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38808">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-38808.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The International Continence Society definition of overactive bladder (OAB) is "urinary urgency, usually accompanied by frequency, nocturia, with or without urge urinary incontinence."<xref ref-type="bibr" rid="article-38808.r1">[1]</xref> It is important to understand that OAB isn't an exact disease but a symptom complex with multiple and distinct etiologies. It is an incredibly embarrassing condition, and many patients are uncomfortable discussing it with their providers. The treatment of OAB includes a three-step algorithm: lifestyle modification, pharmacotherapy, and minimally invasive intervention. Lifestyle and behavioral modifications involve paying close attention to fluid consumption, bladder irritants, bladder training, and pelvic muscle floor therapy. The second line includes using anticholinergics or beta-3 adrenoceptor agonists. The third line consists of the injection of&#x000a0;intradetrusor onabotulinumtoxinA, sacral neuromodulation, and percutaneous posterior tibial nerve stimulation. As per&#x000a0;AUA/SUFU guidelines, in rare cases, fourth-Line Treatment options include augmentation cystoplasty and Urinary Diversion for severe refractor complicated OAB patients.<xref ref-type="bibr" rid="article-38808.r2">[2]</xref></p>
        <p>The medications typically used in OAB are in the antimuscarinic&#x000a0;class. However, their broad side-effect profile must be used cautiously, especially in patients with acute angle-closed glaucoma, older patients, and chronic constipation. Mirabegron, a beta-3 adrenoceptor agonist, has been shown to have high safety and efficacy profile by large random placebo-controlled clinical trials. Mirabegron is used to treat urgency, urge urinary incontinence, and increased urinary frequency found in the overactive bladder.<xref ref-type="bibr" rid="article-38808.r3">[3]</xref> It received approval from the US Food and Drug Administration (FDA) in June 2012 for treating overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.<xref ref-type="bibr" rid="article-38808.r4">[4]</xref>&#x000a0;Mirabegron has been reported to have better tolerance and compliance by patients as compared to antimuscarinics. In this article, we will cover the use of mirabegron.</p>
      </sec>
      <sec id="article-38808.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The human bladder expresses various sympathetic and parasympathetic receptors to help regulate micturition. Activation of the parasympathetic system will result in bladder contraction. Receptors positively affecting bladder contraction and micturition include the M2 and M3 receptor subtypes, which function via the parasympathetic nervous system.<xref ref-type="bibr" rid="article-38808.r5">[5]</xref> These receptors work to increase intracellular calcium and down-regulate cyclic-adenosine, respectively, which will increase muscle contraction. Negatively affecting micturition predominantly includes the sympathetic beta-3 adrenergic receptors.<xref ref-type="bibr" rid="article-38808.r6">[6]</xref> Mirabegron is a beta-3 receptor agonist which will cause detrusor muscle relaxation. Animal studies have shown that beta-3 receptor agonists exhibit a dose-dependent detrusor relaxation (mediated via up-regulation of cyclic-adenosine) during the storage phase of micturition.<xref ref-type="bibr" rid="article-38808.r4">[4]</xref>&#x000a0;This way, mirabegron can aid in the symptomatic relief of OAB and&#x000a0;symptoms of urge urinary incontinence, urgency, and urinary frequency.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Absorption: According to the manufacturer's&#x000a0;product labeling, mirabegron reaches maximum plasma concentrations (Cmax) at approximately 3.5 hours. Steady-state concentrations are achieved within seven days. In adults, there are no clinically significant differences in mirabegron pharmacokinetics when administered with or without food. However, in pediatric patients, fasted Cmax and AUC increased by 170% and 80%, respectively, compared to the fed state following the administration of mirabegron Granules.</p>
        <p>Distribution: Mirabegron has an extensive distribution with the volume of distribution at steady-state (Vss) 1670 L. Mirabegron is bound (approximately 71%) to human plasma proteins, including albumin and alpha-1 acid glycoprotein. Mirabegron distributes to erythrocytes. Mirabegron volume of distribution is relatively higher in pediatric patients and is proportional to body weight.&#x000a0;</p>
        <p>Metabolism: Mirabegron is metabolized in the liver via multiple pathways involving dealkylation, oxidation, glucuronidation, and hydrolysis. Metabolites are not pharmacologically active. Studies have also shown the involvement of butyrylcholinesterase, and UGT in the metabolism of mirabegron, in addition to CYP3A4 and CYP2D6. In poor metabolizers of CYP2D6, mean Cmax and AUC are approximately 16% and 17% higher than in extensive metabolizers of CYP2D6.&#x000a0;</p>
        <p>Excretion: The mean elimination half-life (t1/2) of mirabegron is approximately 50 hours in adult patients and 26 to 31 hours in pediatric patients(mirabegron granules). Renal elimination of mirabegron is primarily through active tubular secretion and glomerular filtration. Approximately&#x000a0; 55% is excreted in the urine, 34% in the feces, and ~25% in the urine(unchanged).</p>
      </sec>
      <sec id="article-38808.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Mirabegron is a once-daily orally administered drug.<xref ref-type="bibr" rid="article-38808.r4">[4]</xref>&#x000a0;It is available in 25 mg or 50 mg strengths. The lower-strength tablet is recommended as a starting dose for patients with severe renal or moderate hepatic impairment. The higher dose tablet is recommended for patients to take with or without food if they tolerate the lower dose.<xref ref-type="bibr" rid="article-38808.r4">[4]</xref>&#x000a0;Other therapeutic routes of administration (intravenous, rectal, enteral, epidural, intracerebral, etc.) for mirabegron are not FDA-approved in the treatment of OAB. Mirabegron may take 4 to 8 weeks before patients see improvements in their symptoms.<xref ref-type="bibr" rid="article-38808.r2">[2]</xref>&#x000a0;Mirabegron is available in extended-release tablets, extended-release granules, and as an oral suspension.</p>
        <p>In addition to monotherapy, combination therapy&#x000a0;with low dose mirabegron (25 mg) and a low dose of solifenacin (5 mg), an anti-muscarinic, has been shown to significantly improve urinary urgency and urgency incontinence when compared to monotherapy. Three large double-blind, randomized controlled trials (SYMPHONY, BESIDE, and SYNERGY) have shown the safety and efficacy of combination therapy.<xref ref-type="bibr" rid="article-38808.r7">[7]</xref><xref ref-type="bibr" rid="article-38808.r8">[8]</xref><xref ref-type="bibr" rid="article-38808.r9">[9]</xref> Recently, the FDA has approved combination therapy for patients with urinary urgency.<xref ref-type="bibr" rid="article-38808.r8">[8]</xref></p>
        <p>
<bold>Use in Specific Patient Populations</bold>
</p>
        <p>
<bold>Patients with Hepatic Impairment</bold>
</p>
        <p>For mild(Child-Pugh Class A&#x000a0; starting dose is 25 mg, and the maximum dose is 50 mg. For moderate hepatic impairment(Child-Pugh Class B).&#x000a0;starting, and the maximum recommended dose is 25 mg. The use of mirabegron is not recommended for severe hepatic impairment (Child-Pugh Class C)<xref ref-type="bibr" rid="article-38808.r10">[10]</xref></p>
        <p>
<bold>Patients with Renal Impairment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>eGFR 30 to 89 mL/min/1.73 m^2 -&#x000a0; maximum dose is&#x000a0;&#x000a0;50 mg once daily</p>
          </list-item>
          <list-item>
            <p>eGFR 15 to 29 mL/min/1.73 m^2 -&#x000a0; maximum dose is 25 mg once daily</p>
          </list-item>
          <list-item>
            <p>eGFR &#x0003c; 15 mL/min/1.73 m^2 or&#x000a0;patient requiring dialysis- Use is not recommended</p>
          </list-item>
        </list>
        <p>
<bold>Pregnancy Considerations</bold>
</p>
        <p>In preclinical studies, decreased fetal weight and increased fetal mortality were observed, and, in rabbits, fetal cardiomegaly was observed. No studies have been conducted regarding the use of mirabegron in pregnant patients to inform a drug-associated risk of miscarriages, significant congenital disabilities, or adverse maternal or fetal outcomes. Use with caution.</p>
        <p>
<bold>Breastfeeding Considerations</bold>
</p>
        <p>There is a lack of safety data regarding using mirabegron during breastfeeding. Hypothetically, mirabegron has moderately high protein binding and relatively low bioavailability, so exposure to the breastfed infant is likely to be low. If the mother requires mirabegron, discontinuing breastfeeding is not a reason. Still, until more data become available, an alternate drug may be preferred while nursing a newborn or preterm infant. Hence, the risk-benefit analysis should be considered while prescribing mirabegron to nursing mothers.<xref ref-type="bibr" rid="article-38808.r11">[11]</xref></p>
      </sec>
      <sec id="article-38808.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse drug reactions to mirabegron are generally mild and tolerable. One study showed that the adverse effects of mirabegron include hypertension (most commonly), nasopharyngitis, and urinary tract infection.<xref ref-type="bibr" rid="article-38808.r12">[12]</xref>&#x000a0; Dry mouth (a common side effect of anti-muscarinic) is six-fold less in mirabegron&#x000a0;because mirabegron does not affect the muscarinic receptors in the salivary glands.<xref ref-type="bibr" rid="article-38808.r12">[12]</xref> Other side effects include tachycardia, headache, back pain, dizziness, palpitations, atrial fibrillation, urticarial reaction, joint pain, and swelling.<xref ref-type="bibr" rid="article-38808.r13">[13]</xref></p>
        <p>Mirabegron is generally considered a safe and effective drug. Mirabegron may also be more useful in the elderly population as the neurocognitive concerns of anti-muscarinic therapy may not be as much of a problem; however, this requires further investigation.&#x000a0;According to the manufacturer's labeling, cases of angioedema have been reported, which can be life-threatening and require immediate drug discontinuation and prompt treatment. Mirabegron can increase blood pressure significantly, and its use is not recommended for use in patients with uncontrolled hypertension. In three years of post-marketing surveillance study, an increase in residual urine volume and urinary retention was recognized as a serious adverse drug reaction related to mirabegron therapy. The risk of urinary retention increases in patients with significant bladder outlet obstruction&#x000a0;with simultaneous use of anti-muscarinic drugs to treat&#x000a0;an overactive bladder. Other common ADRs reported were constipation and dysuria.<xref ref-type="bibr" rid="article-38808.r14">[14]</xref></p>
      </sec>
      <sec id="article-38808.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Previous&#x000a0;hypersensitivity reaction to mirabegron or any&#x000a0;excipients of&#x000a0;tablet or oral suspension is a contraindication to mirabegron use.<bold>&#x000a0;</bold>Mirabegron use correlates with hypertension, and its contraindication includes severe uncontrolled hypertension.<xref ref-type="bibr" rid="article-38808.r15">[15]</xref>&#x000a0;Analysis of hypertension should depend on the discretion of the clinician. Resistant hypertension is defined as blood pressure that remains elevated above 140/90 despite using three antihypertensive drugs at the most tolerated doses, one of which is a diuretic.&#x000a0;In this light, blood pressure optimization should be considered before initiating mirabegron therapy.<xref ref-type="bibr" rid="article-38808.r16">[16]</xref></p>
      </sec>
      <sec id="article-38808.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>It is recommended to monitor blood pressure at baseline and during follow-up visits.&#x000a0;Monitor&#x000a0;quality of life based on the overactive bladder questionnaire (OAB-q) to assess the response to therapy.<xref ref-type="bibr" rid="article-38808.r17">[17]</xref>&#x000a0;Mirabegron is absorbed fairly quickly after oral administration, with maximum plasma concentration achieved in roughly 3 hours.</p>
        <p>The liver&#x02019;s CYP450 system predominantly metabolizes mirabegron. Monitoring and dose adjustment should occur with patients on other medications with a narrow therapeutic index and also undergo metabolism via CYP2D6.<xref ref-type="bibr" rid="article-38808.r13">[13]</xref>&#x000a0;According to American Family Physicians (AAFP), potent inhibitors of the CYP2D6 system are amiodarone, diphenhydramine, fluoxetine, paroxetine, quinidine, ritonavir, and terbinafine. Substrates of the CYP2D6 system are amitriptyline, carvedilol, codeine, donepezil, haloperidol, metoprolol, paroxetine, risperidone, and tramadol. There are no significant inducers. In this light, it is vital to consider all comorbidities and drugs patients are on to prevent undesirable drug-drug interactions. It is recommended to take a thorough history, considering past medical history and review of medications before starting mirabegron therapy.<xref ref-type="bibr" rid="article-38808.r2">[2]</xref></p>
      </sec>
      <sec id="article-38808.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Mirabegron has been shown to have a very broad safety level in humans. Caution is advisable with drugs that exert effects on or are metabolized by the liver, as mirabegron is also hepatically metabolized. Though safe in humans, studies have shown toxicity in dogs in the form of tachycardia and erythema.<xref ref-type="bibr" rid="article-38808.r18">[18]</xref>&#x000a0;Mirabegron is administered to healthy volunteers at up to 400 mg daily, and adverse drug reactions were palpitations and tachycardia. Multiple doses of high-dose mirabegron for ten days showed elevated blood pressure and pulse rate. In suspected overdosage cases, pulse rate, blood pressure, and EKG monitoring are suggested. There is no antidote for mirabegron overdose. Management of mirabegron overdosage is supportive. (This is according to the manufacturer's product labeling).</p>
      </sec>
      <sec id="article-38808.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A study reviewed the interdisciplinary care of urinary incontinence between clinicians, nursing, physical therapy, and pharmacy. Advanced&#x000a0;Practice Registered Nurses and physical therapists&#x000a0;had&#x000a0;a significant role in Long-term Care Facilities. &#x0201c;Prevention Focused Intervention: UI Based on the Health Promotion and Disease Prevention Model&#x0201d;&#x000a0; demonstrated&#x000a0;that interdisciplinary team approaches are crucial to achieving better patient outcomes, as demonstrated by&#x000a0;statistically significant reductions in urinary incontinence episodes.<xref ref-type="bibr" rid="article-38808.r19">[19]</xref>&#x000a0;According to American Urological Association (AUA) guidelines, clinicians should offer &#x003b2;3-adrenoceptor agonists (mirabegron) as second-line therapy.<xref ref-type="bibr" rid="article-38808.r20">[20]</xref><xref ref-type="bibr" rid="article-38808.r2">[2]</xref>&#x000a0;[Level 1, Grade B]</p>
        <p>According to one study, the rate of serious adverse effects of mirabegron was low and not directly related to the drug itself.<xref ref-type="bibr" rid="article-38808.r15">[15]</xref> [Level 1a, Grade A]&#x000a0;Pooled safety data from SCORPIO, ARIES, and CAPRICORN (three large randomized, controlled clinical trials) have shown that there is no dose-response relationship among treatment groups for rates of treatment-emergent adverse effects (TEAE) with mirabegron.<xref ref-type="bibr" rid="article-38808.r21">[21]</xref> Recommendations for managing patients on mirabegron include periodic measurement of blood pressure and symptomatic investigation of urinary retention tract infection; accomplishing this goal is best with an interprofessional healthcare team approach that includes prescribing clinicians (MDs, DOs, NPs, PAs), nursing staff, and pharmacists.&#x000a0;If there are any questions among interprofessional team members regarding the indications, dosing, or interactions of mirabegron, they should reach out to the pharmacist, who can perform medication reconciliation and report back to the prescriber or nurse. Open communication and collaborative efforts will result in improved patient outcomes with a lower incidence of adverse events when this interprofessional approach to care is in place. [Level 5]</p>
      </sec>
      <sec id="article-38808.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38808&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38808">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/38808/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=38808">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-38808.s11">
        <title>References</title>
        <ref id="article-38808.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willis-Gray</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Dieter</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and management of overactive bladder: strategies for optimizing care.</article-title>
            <source>Res Rep Urol</source>
            <year>2016</year>
            <volume>8</volume>
            <fpage>113</fpage>
            <page-range>113-22</page-range>
            <pub-id pub-id-type="pmid">27556018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lightner</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Gomelsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Souter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vasavada</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019.</article-title>
            <source>J Urol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>202</volume>
            <issue>3</issue>
            <fpage>558</fpage>
            <page-range>558-563</page-range>
            <pub-id pub-id-type="pmid">31039103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goulooze</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Rissmann</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Mirabegron.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>762</fpage>
            <page-range>762-4</page-range>
            <pub-id pub-id-type="pmid">25819590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sacco</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bientinesi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Mirabegron: a review of recent data and its prospects in the management of overactive bladder.</article-title>
            <source>Ther Adv Urol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>315</fpage>
            <page-range>315-24</page-range>
            <pub-id pub-id-type="pmid">23205058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abrams</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Buccafusco</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Chapple</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Groat</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Fryer</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Laties</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nathanson</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Pasricha</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Wein</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.</article-title>
            <source>Br J Pharmacol</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>148</volume>
            <issue>5</issue>
            <fpage>565</fpage>
            <page-range>565-78</page-range>
            <pub-id pub-id-type="pmid">16751797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andersson</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>On the Site and Mechanism of Action of &#x003b2;<sub>3</sub>-Adrenoceptor Agonists in the Bladder.</article-title>
            <source>Int Neurourol J</source>
            <year>2017</year>
            <month>Mar</month>
            <day>24</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-11</page-range>
            <pub-id pub-id-type="pmid">28361520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drake</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Chapple</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Esen</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Athanasiou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cambronero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mitcheson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Herschorn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saleem</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>St&#x000f6;lzel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herholdt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>MacDiarmid</surname>
                <given-names>S</given-names>
              </name>
              <collab>BESIDE study investigators</collab>
            </person-group>
            <article-title>Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).</article-title>
            <source>Eur Urol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>70</volume>
            <issue>1</issue>
            <fpage>136</fpage>
            <page-range>136-145</page-range>
            <pub-id pub-id-type="pmid">26965560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abrams</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kelleher</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Staskin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Martan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mincik</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Newgreen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ridder</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paireddy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Maanen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY).</article-title>
            <source>World J Urol</source>
            <year>2017</year>
            <month>May</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>827</fpage>
            <page-range>827-838</page-range>
            <pub-id pub-id-type="pmid">27514371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herschorn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chapple</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Arlandis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mitcheson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Ridder</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stoelzel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paireddy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Maanen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).</article-title>
            <source>BJU Int</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>120</volume>
            <issue>4</issue>
            <fpage>562</fpage>
            <page-range>562-575</page-range>
            <pub-id pub-id-type="pmid">28418102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>95</volume>
            <issue>8</issue>
            <fpage>e2877</fpage>
            <pub-id pub-id-type="pmid">26937922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <chapter-title>Mirabegron</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>7</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">32697458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolff</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Kuchel</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Overactive bladder in the vulnerable elderly.</article-title>
            <source>Res Rep Urol</source>
            <year>2014</year>
            <volume>6</volume>
            <fpage>131</fpage>
            <page-range>131-8</page-range>
            <pub-id pub-id-type="pmid">25328867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharaf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hashim</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Profile of mirabegron in the treatment of overactive bladder: place in therapy.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2017</year>
            <volume>11</volume>
            <fpage>463</fpage>
            <page-range>463-467</page-range>
            <pub-id pub-id-type="pmid">28255232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kato</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tabuchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Uno</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study.</article-title>
            <source>Low Urin Tract Symptoms</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>O152</fpage>
            <page-range>O152-O161</page-range>
            <pub-id pub-id-type="pmid">30079630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corcos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Przydacz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Campeau</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hickling</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Honeine</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Radomski</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Stothers</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wagg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lond</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>CUA guideline on adult overactive bladder.</article-title>
            <source>Can Urol Assoc J</source>
            <year>2017</year>
            <month>May</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>E142</fpage>
            <page-range>E142-E173</page-range>
            <pub-id pub-id-type="pmid">28503229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yaxley</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Thambar</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Resistant hypertension: an approach to management in primary care.</article-title>
            <source>J Family Med Prim Care</source>
            <year>2015</year>
            <season>Apr-Jun</season>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>193</fpage>
            <page-range>193-9</page-range>
            <pub-id pub-id-type="pmid">25949966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freeman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Foley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosa Arias</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vicente</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grill</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kachlirova</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Stari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Choudhury</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2018</year>
            <month>May</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>785</fpage>
            <page-range>785-793</page-range>
            <pub-id pub-id-type="pmid">29254376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmid</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Hovda</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Mirabegron Toxicosis in Dogs: a Retrospective Study.</article-title>
            <source>J Med Toxicol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>160</fpage>
            <page-range>160-167</page-range>
            <pub-id pub-id-type="pmid">29255997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDaniel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ratnani</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fatima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abid</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Surani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Urinary Incontinence in Older Adults Takes Collaborative Nursing Efforts to Improve.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Jul</month>
            <day>12</day>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>e9161</fpage>
            <pub-id pub-id-type="pmid">32802599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapple</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Khullar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nitti</surname>
                <given-names>VW</given-names>
              </name>
              <name>
                <surname>Frankel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Herschorn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaper</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blauwet</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of the &#x003b2;3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.</article-title>
            <source>Eur Urol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-14</page-range>
            <pub-id pub-id-type="pmid">25092537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38808.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vij</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Drake</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical use of the &#x003b2;3 adrenoceptor agonist mirabegron in patients with overactive bladder syndrome.</article-title>
            <source>Ther Adv Urol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>241</fpage>
            <page-range>241-8</page-range>
            <pub-id pub-id-type="pmid">26425139</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
